Novel Immunotherapeutic Approaches for Head and Neck Squamous Cell Carcinoma

Bann, Darrin V.; Deschler, Daniel G.; Goyal, Neerav

doi:10.3390/cancers8100087

Cited by 26 publications

(20 citation statements)

References 105 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the H596 NSCLC xenograft model, the anti-tumor efficacy of ficlatuzumab was verified and increased with combination therapy with gefitinib and cetuximab, an EGFR inhibitor, compared with single agent treatment [ 178 ]. Based on this evidence, clinical trials were initiated to investigate the efficacy of ficlatuzumab for head and neck squamous cell carcinoma, advanced solid tumors, and NSCLC [ 192 , 193 , 194 ]. Preliminary anti-tumor activity and manageable adverse events were observed in phase I clinical trials for advanced solid tumors, and a dose of 20 mg/kg every two weeks was recommended for phase II trials [ 193 ].…”

Section: Hgf Signalingmentioning

confidence: 99%

A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy

Kong

Kim

Jang

et al. 2017

IJMS

127

View full text Add to dashboard Cite

Tumor angiogenesis is a key event that governs tumor progression and metastasis. It is controlled by the complicated and coordinated actions of pro-angiogenic factors and their receptors that become upregulated during tumorigenesis. Over the past several decades, vascular endothelial growth factor (VEGF) signaling has been identified as a central axis in tumor angiogenesis. The remarkable advent of recombinant antibody technology has led to the development of bevacizumab, a humanized antibody that targets VEGF and is a leading clinical therapy to suppress tumor angiogenesis. However, despite the clinical efficacy of bevacizumab, its significant side effects and drug resistance have raised concerns necessitating the identification of novel drug targets and development of novel therapeutics to combat tumor angiogenesis. This review will highlight the role and relevance of VEGF and other potential therapeutic targets and their receptors in angiogenesis. Simultaneously, we will also cover the current status of monoclonal antibodies being developed to target these candidates for cancer therapy.

show abstract

Section: Hgf Signalingmentioning

confidence: 99%

A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy

Kong

Kim

Jang

et al. 2017

IJMS

127

View full text Add to dashboard Cite

show abstract

“…Several vaccination strategies have been evaluated, including the transfection of TAA expression plasmids into patient tissues (DNA vaccines), the administration of TAA peptides (peptide vaccines) and the use of cultured human or microbial cells to generate an antitumour immune response. 98 In HNSCC, several vaccines, such as DNA vaccine INO-3112 and peptide vaccines Mucin-1 and Allo-Vax are currently under investigation in phase I/II clinical trials. In a phase I trial, five patients with advanced HNSCC were treated with peptide vaccines composed of HLA-I and HLA-II restricted melanoma antigen E-A3 or HPV-16 derived peptides, provoking a measurable immune response and acceptable toxicity.…”

Section: Vaccinesmentioning

confidence: 99%

The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches

Economopoulou¹,

Kotsantis²,

Psyrri³

2016

ESMO Open

View full text Add to dashboard Cite

The immune system plays a fundamental role in preventing cancer development by recognising and eliminating tumour cells. The recent success in the field of immunotherapy has confirmed the potential to exploit the immune response as a cancer treatment. Head and neck squamous cell carcinoma (HNSCC) is a malignancy characterized by dismal prognosis and high mortality rate; low survival outcomes in combination with significant toxicity of current treatment strategies highlight the necessity for novel therapeutic modalities. HNSCC is a favourable disease for immunotherapy, as immune escape plays a key role in tumour initiation and progression. T-cell checkpoint inhibitors targeting programmed cell death protein-1 have emerged as novel immunotherapy agents showing remarkable efficacy in HNSCC. However, only a minority of patients derive benefit for single-agent immunotherapies. In this regard, combinatorial immunotherapy approaches represent an alternative strategy that might increase the number of patients who respond to immunotherapy. Focusing on HNSCC, this review will summarise novel combinations of immune checkpoint blockade with other immunotherapy treatment modalities.

show abstract

“…Currently, immune checkpoint inhibitor-targeted drugs, for example, pembrolizumab, have been applied to the first-line treatment of recurrent/metastatic HNSC patients ( 6 , 7 ). However, a large proportion of HNSC patients have failed to respond to immune checkpoint block (ICB) therapies ( 5 , 8 ). Thus, it is urgent to identify the appropriate subtypes of HNSC suitable for immune checkpoint therapy to amplify clinical benefit and enhance the antitumor effect.…”

Section: Introductionmentioning

confidence: 99%

Interferon-Induced Protein 44 Correlated With Immune Infiltration Serves as a Potential Prognostic Indicator in Head and Neck Squamous Cell Carcinoma

et al. 2020

View full text Add to dashboard Cite

Interferon-induced protein 44 (IFI44) containing a guanosine-5′-triphosphate (GTP) binding domain was reported to play a significant role in the immune response to autoimmune disease. However, its roles involved in cancers remain unclear. Here, we detected the expression of IFI44 in The Cancer Genome Atlas (TCGA) Pan-cancer and generally explored the effect of IFI44 on immune infiltration in the tumor microenvironment (TME). The results displayed that IFI44 was mainly located in the cytoplasm and overexpressed in head and neck squamous cell carcinoma (HNSC) samples compared with normal tissues. Survival analysis exhibited that IFI44 was remarkably associated with the clinical outcomes, particularly in lymph node-positive and locally advanced HNSC patients. Biological analysis showed that IFI44 was correlated with such immune biological processes as antigen-presenting and nuclear factor (NF)-kappa B signaling pathways. Immune signature analysis demonstrated that the expression of IFI44 was positively correlated with the infiltration of CD4 + cells and macrophages as well as neutrophils in HNSC. Taken together, these data suggested that IFI44 was abnormally expressed in cancer tissues and indicated the potential impact of IFI44 on the tumor immune infiltration in HNSC.

show abstract

Novel Immunotherapeutic Approaches for Head and Neck Squamous Cell Carcinoma

Cited by 26 publications

References 105 publications

A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy

A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy

The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches

Interferon-Induced Protein 44 Correlated With Immune Infiltration Serves as a Potential Prognostic Indicator in Head and Neck Squamous Cell Carcinoma

Contact Info

Product

Resources

About